secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rezolute, Inc. (RZLT)
CIK:        0001509261
Form:       8-K
Filed at:   2025-03-28T23:59:59+00:00
Accession:  0001104659-25-029429
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Rezolute appoints Erik Harris to board of directors effective March 25, 2025
----------------------------------------------------------------------------

- Erik Harris elected to board effective March 25, 2025; determined independent under Nasdaq rules.
- Harris is CCO and EVP at Ultragenyx Pharmaceutical since June 2019; previously VP at InterMune, Crescendo Bioscience.
- Will receive standard non-employee director cash retainer (pro-rated) and 60,000 stock options at $2.89 exercise price.
- Options vest monthly from March 25, 2025, expiring March 25, 2035; committee assignments pending.
- No family relationships with directors/officers and no material interest in transactions required to disclose.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509261/000110465925029429/0001104659-25-029429-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509261/000110465925029429/tm2510754d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-029429

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer